Table 3. Results of progenitor analyses... | American Society of Hematology

Table 3.

Results of progenitor analyses

	Phase at start of imatinib mesylate treatment	Months of imatinib mesylate treatment	PCR for BCR/ABL, MNCs	FISH, % BCR/ABL⁺ cells*					Months of additional follow-up since last assessment	Clinical status at last follow-up
UPN	Phase at start of imatinib mesylate treatment	Months of imatinib mesylate treatment	PCR for BCR/ABL, MNCs				CD34⁺ cells	CFCs	Months of additional follow-up since last assessment	Clinical status at last follow-up	LTCICs
144	AP	16	NE†	10	6.5	NE		—
		23	NE†	13.2	6.9	NE	10	Cytogenetic relapse (FISH)
177	CP	9	NA	8.5	9	7.5		—
		14	Pos	9.5	7.5	8.5		—
		17	Pos	12.5	NE	NE		—
		22	Pos	Neg	10.8	NE		—
		26	Pos	7.5	Neg	NE	9	CCR
191	AP	8	NA	12.2	11.5	8.5	6	CCR
214	CP	12	Pos	11	11	Neg	8	CCR
222	CP	3	Pos	Neg	Neg	8.5		—
		9	Pos	13	Neg	10.5	8	CCR
234	CP	6	Pos	6.5	9.7	19.5	10	CCR
238	CP	6	Pos	7	12	15.4		—
		12	Pos	Neg	11	NE	6	CCR
248	CP	11	Neg	13	6.5	8.5	7	CCR
255	CP	6	Pos	Neg	Neg	Neg		—
		9	Pos	Neg	Neg	10	10	CCR
256	CP	10	Pos	11.5	11.5	NE	6	CCR
261	AP	18	Pos	16	7.5	8	15	Cytogenetic relapse (karyotype, FISH)
268	CP	4	Pos	Neg	10.5	Neg	13	CCR
276	CP	6	Pos	9.5	Neg	7	10	CCR
283	CP	9	Pos	Neg	Neg	8.5	8	CCR
286	CP	11	Pos	10	8	8	6	CCR

	Phase at start of imatinib mesylate treatment	Months of imatinib mesylate treatment	PCR for BCR/ABL, MNCs	FISH, % BCR/ABL⁺ cells*					Months of additional follow-up since last assessment	Clinical status at last follow-up
UPN	Phase at start of imatinib mesylate treatment	Months of imatinib mesylate treatment	PCR for BCR/ABL, MNCs				CD34⁺ cells	CFCs	Months of additional follow-up since last assessment	Clinical status at last follow-up	LTCICs
144	AP	16	NE†	10	6.5	NE		—
		23	NE†	13.2	6.9	NE	10	Cytogenetic relapse (FISH)
177	CP	9	NA	8.5	9	7.5		—
		14	Pos	9.5	7.5	8.5		—
		17	Pos	12.5	NE	NE		—
		22	Pos	Neg	10.8	NE		—
		26	Pos	7.5	Neg	NE	9	CCR
191	AP	8	NA	12.2	11.5	8.5	6	CCR
214	CP	12	Pos	11	11	Neg	8	CCR
222	CP	3	Pos	Neg	Neg	8.5		—
		9	Pos	13	Neg	10.5	8	CCR
234	CP	6	Pos	6.5	9.7	19.5	10	CCR
238	CP	6	Pos	7	12	15.4		—
		12	Pos	Neg	11	NE	6	CCR
248	CP	11	Neg	13	6.5	8.5	7	CCR
255	CP	6	Pos	Neg	Neg	Neg		—
		9	Pos	Neg	Neg	10	10	CCR
256	CP	10	Pos	11.5	11.5	NE	6	CCR
261	AP	18	Pos	16	7.5	8	15	Cytogenetic relapse (karyotype, FISH)
268	CP	4	Pos	Neg	10.5	Neg	13	CCR
276	CP	6	Pos	9.5	Neg	7	10	CCR
283	CP	9	Pos	Neg	Neg	8.5	8	CCR
286	CP	11	Pos	10	8	8	6	CCR

NE indicates not evaluable; NA, not available; pos, positive; neg, negative.

Upper limit of normal less than or equal to 6% BCR/ABL⁺ cells.

Variant BCR/ABL breakpoint, not amplified by the primers used.